Article Menu
Need Help?
No Article Versions Notes Found
Cite
Levy, P.; Smadja, D.M.; Dorey, J.; Toumi, M.; Meinecke, A.-K.; Bowrin, K.; Briere, J.-B. Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective. J. Mark. Access Health Policy 2019, 7, 1564506. https://doi.org/10.1080/20016689.2018.1564506
Levy P, Smadja DM, Dorey J, Toumi M, Meinecke A-K, Bowrin K, Briere J-B. Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective. Journal of Market Access & Health Policy. 2019; 7(1):1564506. https://doi.org/10.1080/20016689.2018.1564506
Chicago/Turabian StyleLevy, Pierre, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin, and Jean-Baptiste Briere. 2019. "Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective" Journal of Market Access & Health Policy 7, no. 1: 1564506. https://doi.org/10.1080/20016689.2018.1564506
APA StyleLevy, P., Smadja, D. M., Dorey, J., Toumi, M., Meinecke, A.-K., Bowrin, K., & Briere, J.-B. (2019). Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective. Journal of Market Access & Health Policy, 7(1), 1564506. https://doi.org/10.1080/20016689.2018.1564506
